Excited to see our paper in print @EUplatinum: Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.

RT @_backtableUro: Palliative care is about more than end-of-life - it’s about quality of life. Drs. Pauline Filippou & Ashwin Kotwal join….

RT @EUplatinum: 🚨New in @EUPlatinum!.📌 PSMA PET for Prostate Cancer Diagnosis & Staging by @elio_mazzone et al.🧠 This comprehensive meta-an….

RT @UrologyMSK: Congratulations to @arihakimi who was chosen unanimously by the class of 2025 Urologic Oncology Fellows as Teacher of the….

RT @UCSFUrology: Congrats to Kevin Shee for matching into the UCSF UroOnc SUO fellowship program! @KShee11 .#UroOnc #SUO #SUOMatch https://….

RT @CACancerJournal: New review on urothelial carcinoma highlights therapeutic & diagnostic approaches in the perioperative setting, emphas….

RT @MaryFengMD: Thanks for welcoming the second generation Feng to ASCO! What’s your #ASCO25 happy dance? @DrChoueiri @nlinmd @DrKarenKnud….

RT @UrologyMSK: Now published in @JUrology by @UrologyMSK Sherri Donat, @eugene_pietzak, @EKChaMD, @bca_md, @bbmdmsk, @alvincgoh et al:. Pe….

RT @DrSpratticus: @JoeBiden @SocialSecurity @theNCI @CNN @lkayat @jeshoag @MUSICUrology @jimhumd @TylerSbrt 12/12 Summary, men >70yo absolu….

RT @kevndli: Excited to share our latest work, now out in European Urology!. We followed >166k prostate cancer survivors (1999–2019) using….

UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡@bcan_chisolm @UCSFCancer @UCSFUrology.@SimaPorten @jonchou05 @koshkin85 @SamWashUro

RT @urotoday: Revolutionizing #ProstateCancer care! @CChuMD @UCSFUrology presents on the crucial role of PSMA PET in surgical planning & po….

My favorite GR - graduating chief residents discuss their projects from their research year.

RT @tompowles1: 1/2 POTOMAC is the last of the 15 PD(L)1 monotherapy IO R3 trials over 10yrs & >8000 pts in bladder cancer. The summary sho….

A mentee’s success is 100x better than your own. Congratulations @IlanoArielle on her Dean’s Prize for work with @UCSFUrology, as well as upcoming graduation from @UCSFMedicine, and match with @UCSFAnesthesia. 🌟🌟 . @ben_breyer @AShindelGHI @lindsayahampson @pcarroll_

@karissawhiting @IrinaOstrovnaya @AndrewLenis @ClintonTim @drgamzeozcan @drmervebasar @JieFuChen2 @Unclassified1 @rovingatuscap @ARoseBrannon @MFBerger1 @bca_md @MTeoMD @DrRosenbergMSK @IyerGopa @eugene_pietzak @bbmdmsk Full free text here for 50 days:

@karissawhiting @IrinaOstrovnaya @AndrewLenis @ClintonTim @drgamzeozcan @drmervebasar @JieFuChen2 @Unclassified1 @rovingatuscap @ARoseBrannon @MFBerger1 @bca_md @MTeoMD @DrRosenbergMSK @IyerGopa @eugene_pietzak @bbmdmsk.

Thank you to my colleagues @MSKCancerCenter especially mentors @h_alahmadie @DSolit for their support of this work!.

Alternative treatment approaches are urgently needed for UCAH, which remain, individually, rare cancers. A common urothelial origin supports their inclusion in existing trials for UC. This study was limited by its retrospective design and lack of quantification (%) of subtype.

Therapeutic implications are key: ERBB2 alterations in micropapillary UC suggest a potential role for HER2-targeted therapies. Elevated TMB in plasmacytoid, micropapillary, and neuroendocrine subtypes may translate into better responses to immune checkpoint inhibition.

Multi-region sequencing revealed a common urothelial origin in tumors with mixed histologies (and metastasis), although rare exceptions were noted.